Cybin (CYBN.NE) announced that their wholly-owned subsidiary, Adelia Therapeutics, has achieved certain earn-out milestones for the period commencing January 1, 2021. The terms of the milestone earnings were agreed…
Psychedelics
The Jordan Peterson nerve You may have first heard of the Vagus nerve from the infamous breathing coach turned self-help junkie Wim Hof. Hof has become an iconic figure…
Nova Mentis Life Science (NOVA.C) announced they have received Canadian approval for their North American autism clinical study. They received Institutional Review Board (IRB) approval in Canada on its…
MindMed (MNMD.Q) announced they are appointing Dr. Maurizio Fava to their Scientific Advisory Board. Dr. Fava obtained his medical doctorate from the University of Padova School of Medicine, and went…
Core One Labs’ (COOL.C) wholly-owned subsidiary, Akome Biotech, has begun the development of a next-generation psychedelic drug formulation for the purpose of mitigating neurological damage that results from ischemic…
Rollbacks Yesterday Core One Labs (COOL.C) announced an 8:1 share rollback to prepare itself for a Nasdaq listing. Today the company has 114,600,611 common shares outstanding, after the rollback,…
Mind Medicine (MNMD.Q) announced the addition of Dr. Peter Bergethon to their Scientific Advisory Board. Bergethon is a “world-leading” expert in neurology, digital medicine, and central nervous system (CNS)…
Revive Therapeutic (RVV.C) announced they have entered into an agreement with the University of Health Sciences Antigua (UHSA) to collaborate with Revive on their novel psychedelic-assisted therapies and pioneering…
Cybin (CYBN.NE) has selected social anxiety disorder (SAD) and generalized anxiety disorder (GAD) as the targets for their CYB004 proprietary psychedelic molecule. Cybin demonstrated their proof of concept for…
+326% wtf? PharmaTher (PHRM.C), the Vancouver-based psychedelics company is on an impressive run. In the last month, the stock has rocketed from $0.19 CAD up to $0.81 CAD, a…